Association of Sarcopenia With Toxicity and Survival in Postoperative Recurrent Esophageal Squamous Cell Carcinoma Patients Receiving Chemoradiotherapy.
chemoradiotherapy
esophageal squamous cell carcinoma
prognosis
sarcopenia
survival
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
01
2021
accepted:
24
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Sarcopenia has been associated with treatment-related toxicities and poor survival in cancer patients. Our aim was to investigate the prevalence of sarcopenia in postoperative recurrent esophageal squamous cell carcinoma (ESCC) patients receiving chemoradiotherapy (CRT) and evaluate associations with treatment-related toxicity and prognosis. One hundred and eighty-four patients with postoperative locoregional recurrent ESCC receiving CRT between January 2014 and December 2016 were included. The skeletal muscle area (SMA) was measured at the third lumbar vertebra level. Sarcopenia was defined as skeletal muscle index (SMI = SMA/height Sarcopenia was observed in 94 of 184 (51.1%) patients. Sarcopenic patients had significantly higher rates of grade 3-4 toxicities compared to those without sarcopenia (36.2% Sarcopenia is an independent indicator of poor survival in postoperative locoregional recurrent ESCC patients treated with CRT. Early nutritional interventions before treatment may improve the prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Sarcopenia has been associated with treatment-related toxicities and poor survival in cancer patients. Our aim was to investigate the prevalence of sarcopenia in postoperative recurrent esophageal squamous cell carcinoma (ESCC) patients receiving chemoradiotherapy (CRT) and evaluate associations with treatment-related toxicity and prognosis.
METHODS
METHODS
One hundred and eighty-four patients with postoperative locoregional recurrent ESCC receiving CRT between January 2014 and December 2016 were included. The skeletal muscle area (SMA) was measured at the third lumbar vertebra level. Sarcopenia was defined as skeletal muscle index (SMI = SMA/height
RESULTS
RESULTS
Sarcopenia was observed in 94 of 184 (51.1%) patients. Sarcopenic patients had significantly higher rates of grade 3-4 toxicities compared to those without sarcopenia (36.2%
CONCLUSIONS
CONCLUSIONS
Sarcopenia is an independent indicator of poor survival in postoperative locoregional recurrent ESCC patients treated with CRT. Early nutritional interventions before treatment may improve the prognosis.
Identifiants
pubmed: 34307131
doi: 10.3389/fonc.2021.655071
pmc: PMC8297440
doi:
Types de publication
Journal Article
Langues
eng
Pagination
655071Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Xu, Zhou, Yu, Wang, Ji, He, Zhu and Tong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Clin Med. 2019 Oct 09;8(10):
pubmed: 31601040
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Am J Epidemiol. 1998 Apr 15;147(8):755-63
pubmed: 9554417
Clin Nutr. 2016 Jun;35(3):724-30
pubmed: 26065721
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
World J Surg. 2016 Nov;40(11):2698-2704
pubmed: 27272482
J Gastroenterol. 2015 Mar;50(3):323-32
pubmed: 24817668
Radiat Oncol. 2019 Sep 11;14(1):166
pubmed: 31511012
Ann Surg. 2018 Jun;267(6):1100-1104
pubmed: 28437312
Eur Radiol. 2016 May;26(5):1359-67
pubmed: 26334504
Ann Surg. 2017 Nov;266(5):822-830
pubmed: 28796017
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Radiol Oncol. 2020 Mar 27;54(2):237-246
pubmed: 32229679
Dis Esophagus. 2018 Aug 1;31(8):
pubmed: 29846548
Front Oncol. 2018 Oct 22;8:457
pubmed: 30460194
Front Oncol. 2020 Sep 02;10:1581
pubmed: 32984018
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):714-722
pubmed: 32525518
Am J Surg. 2018 May;215(5):813-817
pubmed: 29310892
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Nutr Clin Pract. 2012 Oct;27(5):593-8
pubmed: 22898746
J Thorac Oncol. 2018 Jul;13(7):895-903
pubmed: 29751134
Ann Oncol. 2014 Mar;25(3):638-643
pubmed: 24492674
Radiat Oncol. 2019 Sep 18;14(1):169
pubmed: 31533757
JAMA Oncol. 2016 Jun 1;2(6):782-9
pubmed: 26891703
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
J Clin Oncol. 2018 Sep 20;36(27):2796-2803
pubmed: 30089078
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):199-206
pubmed: 30666831
Ann Oncol. 2012 May;23(5):1095-1103
pubmed: 22003242
Dis Esophagus. 2016 Aug;29(6):627-33
pubmed: 26123787
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Ther Adv Med Oncol. 2020 Aug 18;12:1758835920947612
pubmed: 32913446
Esophagus. 2019 Oct;16(4):345-351
pubmed: 30980203
In Vivo. 2018 May-Jun;32(3):603-610
pubmed: 29695567
Ann Surg Oncol. 2015 Dec;22(13):4432-7
pubmed: 25862583
JAMA Oncol. 2017 Dec 1;3(12):e172319
pubmed: 28796857